SNGX
$1.26
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States.
Recent News
Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky
NasdaqCM:SNGX 1 Year Share Price vs Fair Value Explore Soligenix's Fair Values from the Community and select yours Just...
BC-Most Active Stocks
Gibo Holdings Ltd. 62,368,609 0.0297
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial
Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a proof-of-concept study of SGX945 (dusquetide) in Behçet’s disease, a rare and chronic inflammatory condition. The session volume reached 28.71 million shares, significantly above the stock’s average daily volume of approximately 905,000, according to Benzinga Pro. The company reported that SGX945 achieved the trial’s primary goal of demonstrating biological efficacy in treating oral